OssDsign Establishes U.S. Strategic Surgeon Advisory Board

OssDsign AB is creating a Strategic Surgeon Advisory Board (SSAB) in the United States to help guide and advise the firm on strategic matters.
 
The SSAB will consist of seven U.S. neurosurgical and orthopedic spinal surgeons who will advise the company on matters related to its future direction and priorities such as new product development, regulatory pathways, clinical programs and similar areas of strategic importance. 
 
The SSAB is initially being chaired by Peter Whang, M.D., F.A.C.S., F.A.A.O.S,, associate professor in the Department of Orthopaedics and Rehabilitation at the Yale University School of Medicine. 
 
“I’m delighted to work with OssDsign. The technology that OssDsign is bringing to market is very novel and I expect it to be very beneficial for my patients. I am excited to be serving as an advisor to the company moving forward,” said Dr. Whang.
 
Whang is a U.S. board-certified, fellowship-trained surgeon who specializes in treating diseases of the cervical, thoracic and lumbar regions of the spine and is particularly interested in novel spinal technologies. Whang received his undergraduate degree in biochemistry from Harvard University and his medical degree from the Duke University School of Medicine. He completed his orthopedic surgery residency at the University of California – Los Angeles and received specialized fellowship training in orthopedic and neurosurgical spinal surgery at the Rothman Institute at Thomas Jefferson University in Philadelphia. 

“The opportunity to interact with top U.S. key opinion leaders is important for the future of the company. I am extremely proud that we have been able to attract such talented and renowned surgeons who are deeply knowledgeable about the spine and orthobiologics market. I look forward to working closely with Dr. Whang as well as our other surgeon advisors in the SSAB,” OssDsign CEO Morten Henneveld said.
 
OssDsign is a developer and global provider of next-generation bone replacement products. Based on cutting-edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas. It has a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries. The company has a strong commercial presence in the United States, Europe, and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.